KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Naoto Takahashi, Dong-Wook Kim, Inho Kim, Xin Du, Sung-Eun Lee, Yu Hu, Yoshikane Kikushige, Qian Jiang, Yi Wang, Suning Chen, Huanling Zhu, Tatsunori Goto, Akihiro Tomita, Michiko Ichii, Hirohisa Nakamae, Lei Liu, Beini Liu, Kamel Malek, Tong Zhu, Shengyuan Wu, Jianxiang Wang

Cancer Med 15(6) e72019

PMID42339511
PMCIDPMC13291802
DOI10.1002/cam4.72019
发表日期2026-06-24
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:非 KM 图。
摘要

摘要

ASC4FIRST (ClinicalTrials.gov NCT04971226) is a pivotal phase 3 clinical trial comparing the efficacy and safety of asciminib vs. standard of care (SoC) tyrosine kinase inhibitors (TKIs) in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP). The study demonstrated superior efficacy and a favorable safety profile for asciminib vs. all current SoC TKIs; this subgroup analysis involved 138 patients from East Asian sites enrolled in ASC4FIRST. Patients were randomized to receive either asciminib or investigator-selected TKIs (IS-TKIs: imatinib, bosutinib, dasatinib, or nilotinib) following stratification by risk category and prerandomization-selected TKI (imatinib or second-generation TKI). Consistent with non-East Asian patients, asciminib showed better efficacy in East Asian patients, with a major molecular response (MMR) rate at Week 48 and Week 96 of 64.9% and 77.0% compared to 45.3% and 57.8% for all IS-TKIs combined, respectively (common treatment difference: 19.5% and 20.0%, respectively). Similar results were obtained for patients with imatinib as the prerandomization-selected TKI (MMR rate at Week 48 and Week 96: 67.9% and 78.6% for asciminib compared to 30.8% and 46.2% for imatinib, respectively; common treatment difference: 36.5% and 32.7%, respectively). Asciminib also showed a favorable safety profile in East Asian patients, with lower rates of Grade ≥ 3 adverse events (AEs) and AEs leading to discontinuation compared to IS-TKIs (41.9% vs. 54.0% and 2.7% vs. 9.5%, respectively), consistent with the results from non-East Asian patients. These findings support the use of asciminib as a first-line treatment option for East Asian and non-East Asian patients with CML-CP.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1MMR rates at Week 48 and Week 96 in all asciminib vs. all IS‐TKIs (A, D); asciminib vs. imatinib in the imatinib stratum (B, E); asciminib vs. 2G TKIs in the 2G TKI stratum (C, F). † The common treatment difference and its 95% CI are estimated using the Mantel–Haenszel method after stratifying for prerandomization selected TKI and baseline ELTS risk groups (both IRT data). 2G, second generation; ASC, asciminib; CI, confidence interval; ELTS, European Treatment and Outcome Study Long‐Term Survival; IMA, imatinib; IRT, interactive response technology; IS, investigator selected; MMR, major molecular response; TKI, tyrosine kinase inhibitor.
非 KM Figure
FIGURE 2Cumulative incidence of MMR in all patients treated with asciminib vs. IS‐TKI. A, East Asian patients; B, non‐East Asian patients. Non‐responders were censored at their last molecular assessment date (dark triangle). Discontinuation from treatment for any reason without prior achievement of MMR was considered a competing event (white circle). ASC, asciminib; IS, investigator selected; MMR, major molecular response; TKI, tyrosine kinase inhibitor.
非 KM Figure
FIGURE 3Responses in East Asian and non‐East Asian patients in the asciminib and IS‐TKI arms (top row), asciminib vs. imatinib in the imatinib stratum (middle row), and asciminib vs. 2G TKIs in the 2G TKI stratum (bottom row) for A, EMR at Week 12; B, BCR::ABL1 IS ≤ 1% at Week 48. 2G, second‐generation; ASC, asciminib; EMR, early molecular response; IMA, imatinib; IS, investigator‐selected; TKI, tyrosine kinase inhibitor.
非 KM Figure
FIGURE 4Deep responses at Week 48 and Week 96 in East Asian and non‐East Asian patients in the asciminib and IS‐TKI arms (top row), asciminib vs. imatinib in the imatinib stratum (middle row), and asciminib vs. 2G TKIs in the 2G TKI stratum (bottom row) for: A and C MR 4.0 ; and B and D MR 4.5 , both at Week 48 and Week 96. 2G, second‐generation; ASC, asciminib; IMA, imatinib; IS, investigator‐selected; MR, molecular response; TKI, tyrosine kinase inhibitor.
非 KM Figure
FIGURE 5Adverse events reported in ≥ 10% of patients in any treatment arm. A, East Asian patients; B, non‐East Asian patients. Numbers (n) represent counts of subjects. AEs occurring during treatment or within 30 days of the last study medication are summarized. A subject with multiple severity grades for an AE is only counted under the maximum grade. MedDRA version 27.1, CTCAE version 5.0. ALP, alkaline phosphatase; ALT, alanine aminotransferase; ASC, asciminib; AST, aspartate aminotransferase; Const, constitutional symptoms; COVID‐19, coronavirus disease of 2019; CV, cardiovascular; GGT, gamma‐glutamyl transferase; GI, gastrointestinal; Inf., infections and infestations; IS, investigator selected; Lab., laboratory findings; TKI, tyrosine kinase inhibitor.
非 KM Figure